Klotho Neuroscience Inc. $(KLTO)$, a US-based biogenetics company, has announced a new clinical study in collaboration with the Okinawa Research Center for Longevity Science (ORCLS). The study aims to investigate the role of the human Klotho gene and its secreted protein isoform (s-KL) in promoting longevity and reducing the risks of neurodegenerative diseases, including ALS, Alzheimer's Disease, and Parkinson's Disease, as well as diabetes and cardiovascular disorders. The research will initially focus on analyzing blood levels of the Klotho protein in centenarian samples collected by ORCLS over several decades. Results of this study have not yet been presented and are expected to contribute to the understanding of how maintaining optimum Klotho protein levels may protect against age-related disorders.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。